212 related articles for article (PubMed ID: 24144240)
1. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
Yuan Y; Zaidi SA; Elbegdorj O; Aschenbach LC; Li G; Stevens DL; Scoggins KL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2013 Nov; 56(22):9156-69. PubMed ID: 24144240
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
3. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
[TBL] [Abstract][Full Text] [Related]
4. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y
Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767
[TBL] [Abstract][Full Text] [Related]
5. Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.
Zhang Y; Elbegdorj O; Yuan Y; Beletskaya IO; Selley DE
Bioorg Med Chem Lett; 2013 Jul; 23(13):3719-22. PubMed ID: 23721804
[TBL] [Abstract][Full Text] [Related]
6. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
7. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.
Pelotte AL; Smith RM; Ayestas M; Dersch CM; Bilsky EJ; Rothman RB; Deveau AM
Bioorg Med Chem Lett; 2009 May; 19(10):2811-4. PubMed ID: 19364645
[TBL] [Abstract][Full Text] [Related]
9. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
[TBL] [Abstract][Full Text] [Related]
10. Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
Zheng Y; Obeng S; Wang H; Stevens DL; Komla E; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2018 Dec; 9(12):3028-3037. PubMed ID: 30001114
[TBL] [Abstract][Full Text] [Related]
11. Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
Cami-Kobeci G; Neal AP; Bradbury FA; Purington LC; Aceto MD; Harris LS; Lewis JW; Traynor JR; Husbands SM
J Med Chem; 2009 Mar; 52(6):1546-52. PubMed ID: 19253970
[TBL] [Abstract][Full Text] [Related]
12. Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal κ- and μ-opioid receptor heterodimerization and female-specific spinal morphine antinociception.
Liu NJ; Chakrabarti S; Schnell S; Wessendorf M; Gintzler AR
J Neurosci; 2011 Aug; 31(33):11836-45. PubMed ID: 21849544
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
[TBL] [Abstract][Full Text] [Related]
14. An efficient synthesis of 3-OBn-6β,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist.
Martin DJ; FitzMorris PE; Li B; Ayestas M; Sally EJ; Dersch CM; Rothman RB; Deveau AM
Bioorg Med Chem Lett; 2012 Nov; 22(22):6801-5. PubMed ID: 22771010
[TBL] [Abstract][Full Text] [Related]
15. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for
Obeng S; Wilkerson JL; León F; Reeves ME; Restrepo LF; Gamez-Jimenez LR; Patel A; Pennington AE; Taylor VA; Ho NP; Braun T; Fortner JD; Crowley ML; Williamson MR; Pallares VLC; Mottinelli M; Lopera-Londoño C; McCurdy CR; McMahon LR; Hiranita T
J Pharmacol Exp Ther; 2021 Mar; 376(3):410-427. PubMed ID: 33384303
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking.
Dumitrascuta M; Bermudez M; Trovato O; De Neve J; Ballet S; Wolber G; Spetea M
Molecules; 2021 May; 26(11):. PubMed ID: 34071603
[TBL] [Abstract][Full Text] [Related]
20. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
